Shares of Evoke Pharma Inc. (NASDAQ:EVOK) gapped up prior to trading on Friday . The stock had previously closed at $2.71, but opened at $3.03. Evoke Pharma shares last traded at $3.86, with a volume of 20,582,656 shares.

A number of analysts recently weighed in on the stock. FBR & Co reaffirmed a “buy” rating on shares of Evoke Pharma in a research note on Saturday, May 14th. Zacks Investment Research lowered shares of Evoke Pharma from a “buy” rating to a “hold” rating in a research note on Thursday, May 5th. Brean Capital reaffirmed a “buy” rating on shares of Evoke Pharma in a research note on Thursday, May 12th. Rodman & Renshaw reissued a “buy” rating on shares of Evoke Pharma in a research report on Thursday, May 12th. Finally, Noble Financial lowered shares of Evoke Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, July 19th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $13.34.

The company’s market cap is $18.97 million. The stock’s 50-day moving average is $5.82 and its 200-day moving average is $4.73.

Evoke Pharma (NASDAQ:EVOK) last issued its quarterly earnings data on Wednesday, May 11th. The specialty pharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by $0.04. Analysts forecast that Evoke Pharma Inc. will post ($1.43) EPS for the current year.

In related news, major shareholder Parters Vii L. P. Domain sold 344,120 shares of the firm’s stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $4.70, for a total transaction of $1,617,364.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.